XML 28 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 11 - Grants and Collaboration Revenue
3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Government Grants and Contracts [Text Block]
11.
     Grants and Collaboration Revenue
 
We receive ongoing payments pursuant to grants and contracts from the National Institute of Allergy and Infectious Diseases (NIAID) in support of our vaccine research and development efforts. We record revenue associated with government grants and contracts as the reimbursable costs are incurred. During the
three
-month periods ended
March 31, 2018
and
2017,
we recorded
$216,299
and
$295,735,
respectively, of revenues associated with these grants and contracts. As of
March 31, 2018,
there is an aggregate of
$265,396
in approved grant funds available for use.
 
During the
first
quarter of
2018,
we recorded
$5,000
of revenue associated with a collaboration with the U.S. Naval Research Laboratory (USNRL) for development of high-quality antibodies useful for detection of Lassa virus.